InsiderSource

Lyssikatos Joseph P

CHIEF SCIENTIFIC OFFICER, Director, Chief Scientific Officer · SEC CIK 1967150
Insider at ELVN Enliven Therapeutics, Inc.
Advertisement

Buy track record

How this insider's open-market purchases have performed
This insider has no open-market purchases in the records we parsed, so there's no buy track record to score. Their full filing history is below.
Advertisement
Open-market buys
$0
0 trades
Open-market sells
$11.38M
56 trades
Net flow
−$11.38M
Net selling
Total filings
68
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Oct 10, 2024 ΔOwn −1.2%

Lyssikatos Joseph P sold $368.2K of ELVN, trimming their stake 1%.

−$368.2K
13,167 sh @ $28
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Oct 8, 2024 ΔOwn −0.7%

Lyssikatos Joseph P sold $206.9K of ELVN, trimming their stake 1%.

−$206.9K
7,522 sh @ $28
Advertisement
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Sep 3, 2024 ΔOwn −1.1%

Lyssikatos Joseph P sold $268.7K of ELVN, trimming their stake 1%.

−$268.7K
11,950 sh @ $22
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jul 31, 2024 ΔOwn −1.1%

Lyssikatos Joseph P sold $314.8K of ELVN, trimming their stake 1%.

−$314.8K
11,797 sh @ $27
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jul 3, 2024 ΔOwn −1.1%

Lyssikatos Joseph P sold $274.7K of ELVN, trimming their stake 1%.

−$274.7K
12,000 sh @ $23
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed May 1, 2024 ΔOwn −92%

Lyssikatos Joseph P sold $196.3K of ELVN, trimming their stake 92%.

−$196.3K
10,987 sh @ $18
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed May 1, 2024 ΔOwn −100%

Lyssikatos Joseph P sold $18.7K of ELVN, trimming their stake 100%.

−$18.7K
1,013 sh @ $18
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Apr 15, 2024 ΔOwn −100%

Lyssikatos Joseph P sold $751.3K of ELVN, trimming their stake 100%.

−$751.3K
30,000 sh @ $25
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Apr 3, 2024 ΔOwn −20%

Lyssikatos Joseph P sold $41.7K of ELVN, trimming their stake 20%.

−$41.7K
2,352 sh @ $18
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Apr 3, 2024 ΔOwn −99%

Lyssikatos Joseph P sold $180.1K of ELVN, trimming their stake 99%.

−$180.1K
9,577 sh @ $19
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Apr 3, 2024 ΔOwn −100%

Lyssikatos Joseph P sold $1.4K of ELVN, trimming their stake 100%.

−$1.4K
71 sh @ $19
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Mar 4, 2024 ΔOwn −85%

Lyssikatos Joseph P sold $166.2K of ELVN, trimming their stake 85%.

−$166.2K
10,195 sh @ $16
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Mar 4, 2024 ΔOwn −100%

Lyssikatos Joseph P sold $30.9K of ELVN, trimming their stake 100%.

−$30.9K
1,805 sh @ $17
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, CHIEF SCIENTIFIC OFFICER · Open-market sale · filed Jan 31, 2024 ΔOwn −100%

Lyssikatos Joseph P sold $190.3K of ELVN, trimming their stake 100%.

−$190.3K
12,000 sh @ $16
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, Chief Scientific Officer · Open-market sale · filed Jan 3, 2024 ΔOwn −76%

Lyssikatos Joseph P sold $129.3K of ELVN, trimming their stake 76%.

−$129.3K
9,151 sh @ $14
ELVN
Enliven Therapeutics, Inc.
Sell Lyssikatos Joseph P · Director, Chief Scientific Officer · Open-market sale · filed Jan 3, 2024 ΔOwn −100%

Lyssikatos Joseph P sold $42.1K of ELVN, trimming their stake 100%.

−$42.1K
2,849 sh @ $15

Frequently asked questions

How is Lyssikatos Joseph P's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from Lyssikatos Joseph P's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.